+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • April 2023
  • GlobalData
  • Vaxart Inc
  • ID: 4432328
Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

  • Mar 29, 2023: Vaxart to present at World Vaccine Congress Washington 2023 on April 5-6
  • Mar 15, 2023: Vaxart Provides business update and Full Year 2022 financial results
  • Mar 08, 2023: Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
  • Feb 10, 2023: What might the end of the Covid-19 emergency mean for the drug development pipeline?

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Vaxart Inc - Key Facts
  • Vaxart Inc - Key Employees
  • Vaxart Inc - Key Employee Biographies
  • Vaxart Inc - Major Products and Services
  • Vaxart Inc - History
  • Vaxart Inc - Company Statement
  • Vaxart Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Vaxart Inc - Business Description
  • R&D Overview
  • Vaxart Inc - Corporate Strategy
  • Vaxart Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Vaxart Inc - Strengths
  • Vaxart Inc - Weaknesses
  • Vaxart Inc - Opportunities
  • Vaxart Inc - Threats
  • Vaxart Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Vaxart Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 29, 2023: Vaxart to present at World Vaccine Congress Washington 2023 on April 5-6
  • Mar 15, 2023: Vaxart Provides business update and Full Year 2022 financial results
  • Mar 08, 2023: Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
  • Feb 10, 2023: What might the end of the Covid-19 emergency mean for the drug development pipeline
  • Dec 19, 2022: Vaxart Names Phillip Lee as Chief Financial Officer
  • Nov 08, 2022: Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
  • Sep 07, 2022: Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
  • Aug 31, 2022: Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer
  • Aug 25, 2022: Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
  • Aug 08, 2022: Vaxart Appoints W. Mark Watson to its Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Vaxart Inc, Key Facts
  • Vaxart Inc, Key Employees
  • Vaxart Inc, Key Employee Biographies
  • Vaxart Inc, Major Products and Services
  • Vaxart Inc, History
  • Vaxart Inc, Subsidiaries
  • Vaxart Inc, Key Competitors
  • Vaxart Inc, Ratios based on current share price
  • Vaxart Inc, Annual Ratios
  • Vaxart Inc, Interim Ratios
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Vaxart Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Vaxart Inc, Performance Chart (2018 - 2022)
  • Vaxart Inc, Ratio Charts
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Moderna Inc
  • Baxter International Inc
  • AstraZeneca UK Ltd
  • Selva Therapeutics Inc
  • Astellas Pharma Inc
  • Genexine Inc
  • Sanofi
  • Inovio Pharmaceuticals Inc
  • Abbott Laboratories
  • Janssen Pharmaceuticals Inc
  • Pfizer Inc
  • Advaxis Inc
  • GSK plc
  • Medicago Inc
  • Takeda Pharmaceutical Co Ltd
  • CSL Ltd
  • Novavax Inc
  • Moderna Inc
  • Novavax Inc
  • Ayala Pharmaceuticals Inc.
  • Genexine Inc
  • Selva Therapeutics Inc
  • Janssen Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • Medicago Inc